# US 2023/0068783 A1 · Agents that interfere with il-1beta receptor signalling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068783 A1
- Document ID: US20230068783A1
- Status: Published application
- Kind: A1
- Application number: 17/759,154
- Filed: 2020-07-09
- Published: 2023-03-02
- Earliest claimed: 2020-01-21
- Assignees: Tavotek Biotherapeutics (Hong Kong) Limited
- Applicants: Tavotek Biotherapeutics (Hong Kong) Limited
- Inventors: Di ZHANG; Susan TAM; Minseon CHO; Lihua SHI; Man-Cheong FUNG
- Web page: https://patentgrep.com/patent/US20230068783A1

## CPC

- C07K 16/245: {IL-1}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to antibodies that specifically bind and neutralize interleukin-1β (IL-1β), and to the use of such antibodies for the therapeutic treatment of IL-1β-mediated diseases and disorders.

## Claims

### Claim 1

An isolated antibody or an antigen-binding fragment thereof that specifically binds to IL-1β and neutralizes, inhibits, blocks, abroqates reduces, or interferes with an activity of IL-1β.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antiqen-bindinq fragment comprises heavy chain complementarity determining region (CDR) sequences HCDR1, HCDR2, and HCDR3 set forth as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively.

### Claim 4 (depends on 3)

The antibody or antigen-binding fragment of claim 3, wherein the antibody or antiqen-bindinq fragment comprises light chain complementarity determining region (CDR) sequences LCDR1, LCDR2, LCDR3 set forth as SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antiqen-bindinq fragment is a humanized antibody or antiqen-bindinq fragment.

### Claim 6 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a heavy chain variable region set forth as SEQ ID NO: 9.

### Claim 7 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a light chain variable region set forth as SEQ ID NO: 10.

### Claim 8 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a light chain variable region set forth as SEQ ID NO: 11.

### Claim 9 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a light chain variable region set forth as SEQ ID NO: 12.

### Claim 10 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a light chain variable region set forth as SEQ ID NO: 13.

### Claim 11 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a human IgG1 heavy chain sequence set forth as SEQ ID NO: 14.

### Claim 12 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a human light chain sequence set forth as SEQ ID NO: 15.

### Claim 13 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a human light chain sequence set forth as SEQ ID NO: 16.

### Claim 14 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a human light chain sequence set forth as SEQ ID NO: 17.

### Claim 15 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antiqen-bindinq fragment comprises a human light chain sequence set forth as SEQ ID NO: 18.

### Claim 16 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody is an IgG1, IgG2, IgG3, or IgG4 isotype.

### Claim 17 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody has one or more Fc mutations that extend the half-life of the mutated antibody as compared to the parental wild-type antibody.

### Claim 18 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody has one or more Fc mutations that enhance resistance of the mutated antibody to proteolytic degradation by a protease as compared to the parental wild-type antibody.

### Claim 19 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody has one or more Fc mutations that reduce or eliminate the effector functions of the mutated antibody as compared to the parental wild-type antibody.

### Claim 20 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody has L234A, L235A, M428L, and N434S Fc mutations that extend the half-life of the mutated antibody and reduce the effector functions of the mutated antibody, residue numbering according to the EU Index, as compared to the parental wild-type antibody.

### Claim 21 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment comprises a human IgG1 heavy chain set forth as SEQ ID NO: 31.

### Claim 22 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody has E233P, L234A, L235A, F405L, M428L, and N434S Fc mutations and has G236 deleted to enhance resistance of the mutated antibody to proteolytic degradation, extend the half-life of the mutated antibody, and reduce the effector functions of the mutated antibody, residue numbering according to the EU Index, as compared to the parental wild-type antibody.

### Claim 23 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment comprises a human IgG1 heavy chain set forth as SEQ ID NO: 32.

### Claim 24

(canceled)

### Claim 25 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody or antiqen-bindinq fragment blocks the binding of monkey IL-1β to its receptor IL-1βRI.

### Claim 26 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody or antiqen-bindinq fragment neutralizes, reduces, or interferes with a functional activity of IL-1βR with its receptor IL-1βRI.

### Claim 27

(canceled)

### Claim 28 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody or fragment inhibits IL-1β-driven IL-6 release from human fibroblast cell MRC-5 in a cytokine release assay.

### Claim 29 (depends on 4)

The antibody or antigen-binding fragment of claim 4, wherein the antibody or antiqen-bindinq fragment inhibits IL-1β-driven knee joint arthritis in a mouse arthritis model.

### Claim 30 (depends on 4)

An isolated polynucleotide encoding the antibody or antiqen-bindinq fragment of claim 4.

### Claim 31 (depends on 30)

A vector comprising the polynucleotide of claim 30.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

A host cell comprising the vector of claim 31.

### Claim 34 (depends on 4)

A method of producing the antibody or antigen-binding fragment of claim 4, comprising;
culturing a host cell comprising a vector comprising a polynucleotide encoding the antibody or antiqen-bindinq fragment of claim 4 in conditions wherein the antibody or antiqen-bindinq fragment is expressed, and isolating the antibody or fragment.

### Claim at position 35

35-37. (canceled)

### Claim 38 (depends on 4)

A method for treating an IL-1β3 mediated disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of the antibody or antiqen-bindinq fragment of claim 4.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the IL-1β mediated disease or disorder is an inflammatory disease, a cardiovascular disease, type 2 diabetes, lung cancer, breast cancer, or pancreatic cancer.

### Claim at position 38

40-44. (canceled)
